Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization
- PMID: 25410169
- DOI: 10.5935/0004-2749.20140054
Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization
Abstract
Purpose: To compare the effects of bevacizumab applied either subconjunctivally or topically, in a rat model of corneal neovascularization induced by alkali burn.
Methods: The right corneas of 24 Wistar-Albino rats were cauterized with silver nitrate sticks. The rats were divided randomly and equally into three groups: no treatment control (n=8), subconjunctival bevacizumab treatment (n=8), and topical bevacizumab treatment (n=8). Immediately following cauterization, the subconjunctival group was treated with a 0.05 ml (1.25 mg) bevacizumab subconjunctival injection. The topical group was treated with 10 mg/ml bevacizumab twice daily, and the control group received subconjunctival saline injections twice daily. The burn stimulus and neovascularization scores were evaluated using a technique previously described by Mahoney and Waterbury. Digital photographs were obtained before the eyes were enucleated and corneal sections were then analyzed by histopathology.
Results: The mean burn stimulus score was 1.86 ± 0.6 and there was no statistical difference between the groups (p=0.730). The mean neovascularization scores in the subconjunctival and topical bevacizumab groups were statistically lower than the control group (p<0.05). The mean percentage area of corneal neovascularization was 82.5 ± 22.1 in the control group, 42.7 ± 15.0 in the subconjunctival group, and 55.8 ± 18.2 in the topical group. The differences between the control and treatment groups were statistically significant (p<0.05). Histopathology showed that the treatment groups presented less neovascularization, inflammation, and fibroblast activity than the control group (p<0.05).
Conclusions: This study demonstrates that both subconjunctival and topical administrations of bevacizumab inhibit corneal neovascularization and decrease inflammation and fibroblast activity in a rat model of corneal neovascularization induced by alkali burn.
Similar articles
-
Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model.Ophthalmic Res. 2012;48(3):118-23. doi: 10.1159/000337139. Epub 2012 Apr 24. Ophthalmic Res. 2012. PMID: 22538642
-
Effects of subconjunctivally injected bevacizumab, etanercept, and the combination of both drugs on experimental corneal neovascularization.Can J Ophthalmol. 2013 Apr;48(2):115-20. doi: 10.1016/j.jcjo.2012.12.003. Can J Ophthalmol. 2013. PMID: 23561605
-
Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs.Cornea. 2008 Apr;27(3):357-62. doi: 10.1097/ICO.0b013e318160d019. Cornea. 2008. PMID: 18362668
-
Effect of topical motesanib in experimental corneal neovascularization model.Int Ophthalmol. 2023 Aug;43(8):2989-2997. doi: 10.1007/s10792-023-02685-3. Epub 2023 Mar 27. Int Ophthalmol. 2023. PMID: 36971928 Review.
-
Challenges and strategies for the delivery of biologics to the cornea.J Control Release. 2021 May 10;333:560-578. doi: 10.1016/j.jconrel.2021.04.008. Epub 2021 Apr 16. J Control Release. 2021. PMID: 33857565 Review.
Cited by
-
Effect of metronidazole ophthalmic solution on corneal neovascularization in a rat model.Int Ophthalmol. 2019 May;39(5):1123-1135. doi: 10.1007/s10792-018-0922-2. Epub 2018 Apr 26. Int Ophthalmol. 2019. PMID: 29700650
-
Novel artemisinin derivative P31 inhibits VEGF-induced corneal neovascularization through AKT and ERK1/2 pathways.Heliyon. 2024 Apr 20;10(8):e29984. doi: 10.1016/j.heliyon.2024.e29984. eCollection 2024 Apr 30. Heliyon. 2024. PMID: 38699723 Free PMC article.
-
Intrastromal versus subconjunctival anti-VEGF agents for treatment of corneal neovascularization: a rabbit study.Eye (Lond). 2021 Nov;35(11):3123-3130. doi: 10.1038/s41433-020-01347-3. Epub 2021 Jan 19. Eye (Lond). 2021. PMID: 33469129 Free PMC article.
-
The molecular mechanisms of action of PPAR-γ agonists in the treatment of corneal alkali burns (Review).Int J Mol Med. 2016 Oct;38(4):1003-11. doi: 10.3892/ijmm.2016.2699. Epub 2016 Aug 4. Int J Mol Med. 2016. PMID: 27499172 Free PMC article.
-
Salubrinal Ameliorates Inflammation and Neovascularization via the Caspase 3/Enos Signaling in an Alkaline-Induced Rat Corneal Neovascularization Model.Medicina (Kaunas). 2023 Feb 9;59(2):323. doi: 10.3390/medicina59020323. Medicina (Kaunas). 2023. PMID: 36837524 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources